PD-ICB (n=42) | PD-no-ICB (n=42) | p Value | |
Age (years) | 62.6±9.6 | 62.2±9.1 | 0.8 |
Gender (M/F) | 30/12 | 28/14 | 0.6 |
UPDRS-III | 22.3±9.6 | 20.6±9.8 | 0.3 |
H&Y | 1.8±0.5 | 1.7±0.5 | 0.3 |
Schwab & England (%) | 94.4±6.1 | 93.5±6.7 | 0.5 |
Disease duration from symptoms onset to baseline (months) | 19.9±13.5 | 21.7±23.9 | 0.6 |
Disease duration from symptoms onset to follow-up (months)* | 43.8±17.3 | 61.7±29.5 | 0.0001 |
LEDD total (mg)* | 353.3±281.3 | 539.0±342.9 | 0.01 |
LEDD D-Ag (mg)* | 57.62±96.7 | 53.6±87.1 | 0.9 |
MoCA | 27.4±2.1 | 28.3±1.6 | 0.03 |
Symbol digit modalities test | 41.7±12.0 | 48.6±11.6 | 0.9 |
HVLT-R free recall | 24.2±5.7 | 24.8±5.4 | 0.6 |
HVLT-R recognition discrimination | 21.5±7.8 | 23.3±6.2 | 0.3 |
Phonemic fluency | 12.9±4.6 | 13.8±4.2 | 0.3 |
Benton judgement of line orientation | 12.7±2.2 | 13.4±1.5 | 0.2 |
Letter number sequencing | 10.3±3.1 | 10.5±2.2 | 0.6 |
Semantic fluency | 47.4±11.7 | 41.6±8.6 | 0.5 |
STAI-state | 36.2±10.6 | 31.1±9.5 | 0.02 |
STAI-trait | 35.4±9.6 | 30.8±10.0 | 0.01 |
STAI-total | 71.5±19.2 | 61.9±18.4 | 0.009 |
GDS | 2.8±2.24 | 2.5±3.0 | 0.2 |
UPSIT | 20.9±9.4 | 21.9±8.5 | 0.6 |
SCOPA_AUT | 11.6±7.6 | 7.4±3.8 | 0.004 |
RBDSQ (Y/N) (%) | 22/20 (52.3%) | 12/30 (28.5%) | 0.03 |
*At the time of QUIP conversion from negative to positive in PD-ICB or at the last available follow-up visit in PD-no-ICB.
D-Ag, dopamine agonists; GDS, Geriatric Depression Scale; H&Y, Hoehn and Yahr stage; HVLT, Hopkins verbal learning test; LEDD, levodopa equivalent daily dose; MoCA, Montreal cognitive assessment; RBDSQ, Rapid Eye Movement Sleep Behaviour Disorder Questionnaire (yes ≤ 5, no ≥5); SCOPA-AUT, Scales for Outcomes in Parkinson’s disease-Autonomic; STAI, State-Trait Anxiety Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale.; UPSIT, University of Pennsylvania smell identification test.